Mars Sample Return and Biocontainment

1998 ◽  
Vol 3 (1) ◽  
pp. 30-32
Author(s):  
Margaret S. Race

In its continuing exploration of the solar system, NASA currently has plans to launch a sample return mission to Mars as early as 2005. The design of such a mission will utilize a variety of contamination control measures, both on the outbound flight to Mars and during the return to Earth of the spacecraft and sample return canister. Biocontainment and quarantine will most certainly be required at a receiving facility where a comprehensive battery of tests will be done to determine if any living, replicating entities are included in the samples and whether the returned materials are harmful in any way to Earth's biota or ecosystems. The task of developing hardware, facilities, laboratory protocols, operations plans and certification standards for extraterrestrial materials will require input from many disciplines, including biosafety and public health experts. By combining basic principles of biocontainment with information about the nature and capabilities of microorganisms, a preliminary protocol has been developed for handling, containing and testing extraterrestrial samples. Plans for biocontainment facilities, quarantine and testing methods for Mars sample return missions will also be important in planning future extraterrestrial sample returns from comets, moons and asteroids which also have the potential for harboring life.

2020 ◽  
Author(s):  
Paul Coleman ◽  
Roger Gajraj ◽  
Joht Singh Chandan ◽  
Anjana Roy ◽  
Victoria Lumby ◽  
...  

Background: SARS-CoV-2 can spread rapidly within correctional facilities. On 22nd March 2020, following identification of a confirmed COVID-19 case in a prisoner in Prison A (UK), an Outbreak Control Team was convened consisting of prison staff and public health experts from Public Health England and the UK National Health Service. Methods: At the start of the outbreak, four prisoners and 40 staff were isolating with COVID-19 symptoms. An outbreak was declared and full prison lockdown implemented. Prompt implementation of novel outbreak control measures prevented an explosive prison outbreak, specifically establishment of dedicated isolation and cohorting units, including (i) Reverse Cohorting Units (RCUs) for accommodating new detainees; (ii) Protective Isolation Units (PIUs) for isolating symptomatic prisoners (new detainees and existing residents), and (iii) Shielding Units (SUs) to protect medically vulnerable prisoners. Findings: In total, 120 probable and 25 confirmed cases among prisoners and staff were recorded between March and June 2020. Among prisoners, there were six possible, 79 probable, and three confirmed cases. Among staff, there were 83 possible, 79 probable, and 22 confirmed cases. Testing of symptomatic prisoners was limited for most of the outbreak, with only 33% of probable cases tested. This explains the low number of confirmed cases (three) among prisoners despite the large number of probable cases (n=81; 92%). Over 50% of the initial cases among prisoners were on the two wings associated with the index case. Interpretation: Rapid transmission of SARS-COV-2 was prevented through proactive steps in identifying and isolating infected prisoners (and staff), cohorting new admissions and shielding vulnerable individuals. These novel and cost-effective approaches can be implemented in a wide range of correctional facilities globally and proved effective even in the absence of mass testing.


2014 ◽  
Vol 66 (1) ◽  
Author(s):  
Takashi Mikouchi ◽  
Mutsumi Komatsu ◽  
Kenji Hagiya ◽  
Kazumasa Ohsumi ◽  
Michael E Zolensky ◽  
...  

2021 ◽  
Vol 11 (6) ◽  
pp. 475
Author(s):  
Joaquín Dopazo ◽  
Douglas Maya-Miles ◽  
Federico García ◽  
Nicola Lorusso ◽  
Miguel Ángel Calleja ◽  
...  

The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems.


Sign in / Sign up

Export Citation Format

Share Document